Historically, oncology drug development has evolved on what may seem to be a different planet, at least relative to mainstream clinical pharmacology.
Whereas traditional drug development utilizes standard tools of randomization, pharmacokinetic data, and blood-based biomarkers to optimize dosing, oncology has primarily utilized safety data (i.e., maximally tolerated dose) to guide dose selection.